With Anthropic's Mythos and Fable 5 still walled off by U.S. export restrictions, Asian labs are moving to capture the market the restrictions vacated. Japan's Sakana AI unveiled Fugu, named for the blowfish, which the company says “stands shoulder-to-shoulder with leading models like Anthropic's Fable 5 and Mythos Preview.” Fugu is built agent-first: rather than maximizing a single monolithic model, it is designed to orchestrate access to other models through their APIs, coordinating usage across many systems. Sakana was co-founded by David Ha and Llion Jones, both Google alumni and the latter a co-author of the original transformer paper, alongside Ren Ito, a former Mercari and Stability AI executive. The lab specializes in affordable generative models that work well on small datasets and are tuned for Japanese language and culture, and it says the research underpinning Fugu was presented at ICLR this spring.
The explicit pitch is exposure reduction: Sakana is targeting Japanese businesses and government agencies that want frontier-level capability without the risk of tightening export controls cutting them off. The company was careful not to declare a permanent regional shift away from U.S. models, characterizing the moment as a window rather than a lasting realignment toward any one set of players. In parallel, a Chinese vendor unveiled Tulongfeng, which it positions to go head-to-head with Mythos on cybersecurity, plus two security-specific tools: one built to automatically discover software vulnerabilities and a second, Yitianzhen, built to automate cyber defense and incident response.
The practical stakes are concentrated in two areas. First, agentic orchestration: both Fugu and the Chinese tools assume a world in which the model is a controller routing work to other models and tools, not a single oracle. Second, the security domain, where Mythos's restricted status was justified partly by its offensive-cyber potential, is exactly where the new entrants are planting their flags. If buyers in Asia standardize on models that carry no U.S. export risk, the commercial cost of the restrictions falls on the leading U.S. labs that cannot serve those customers.